ABSTRACT-Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that plays a major role in the pathogenesis of sepsis. Some studies have indicated that glucocorticoids increase MIF production in physiological conditions. The goal of this study was to determine whether glucocorticoid treatment also upregulates MIF production in sepsis. Male NMRI mice (6Y10 weeks old) underwent laparotomy, proximal ligation of the cecum, and double perforation with a 19-gauge needle (cecal ligation and puncture). Mice were randomly treated with saline (control) or dexamethasone at doses of 0.1, 1, or 10 mg/kg ip. At 6 or 18 h postoperatively, 10 mice per group were euthanized; and blood, peritoneal fluid, liver, lung, kidney, and heart tissue samples were retrieved. MIF, IL-6, TNF-!, and IL-10 were measured by enzymelinked immunosorbent assay. Sepsis induced by cecal ligation and puncture produced a marked increase in MIF and cytokine levels in plasma and peritoneal fluid. Treatment with dexamethasone 10 mg/kg decreased MIF levels in plasma after 18 h, but there was no effect of dexamethasone on MIF production locally in the peritoneal cavity or in the liver, lungs, heart, or kidneys. We conclude that glucocorticoid treatment does not upregulate MIF production in sepsis.
INTRODUCTION
Glucocorticoids are an essential component of the stress response to severe infections, particularly septic shock. One of their main functions is to limit overexpression of the immunological system. In animal models of septic shock, adrenalectomy is associated with more inflammation and poorer survival (1) . Clinical studies have shown that functional adrenal insufficiency is common among septic shock patients and constitutes an independent risk factor for mortality (2) . Recent studies have indicated that moderate-dose glucocorticoid therapy may increase survival in septic shock patients (3) .
Glucocorticoids are powerful inhibitors of the production of proinflammatory cytokines. Macrophage migration inhibitory factor (MIF) remains a remarkable exception because it was shown in vitro that low concentrations of glucocorticoids induce rather than inhibit MIF production in mouse macrophages and T lymphocytes (4) . In rats, dexamethasone administration increases MIF content in plasma and several tissues (4, 5) . MIF, in turn, overrides the anti-inflammatory effects of glucocorticoids and thus may potentially induce glucocorticoid resistance (4) .
MIF is a pleiotropic proinflammatory cytokine involved in the pathogenesis of septic shock and other inflammatory diseases (6) . In experimental models of sepsis, MIF expression has been found to be increased, whereas administration of recombinant MIF (rMIF) increased the inflammatory response and resulted in higher mortality rates (6Y9). Neutralization of MIF or deletion of its gene was protective in the same models (6Y8). In patients with sepsis, MIF levels are increased and they correlate with outcome (10) .
The effects of glucocorticoids on MIF production have not been studied in sepsis. Upregulation of MIF can potentially be a drawback of glucocorticoid treatment and might have the paradoxical consequence of further enhancing glucocorticoid resistance. The aim of this study was to determine whether dexamethasone treatment increased MIF production in a peritonitis model in mice.
MATERIALS AND METHODS

Animals
The protocol was approved by the Institutional Animal Care and Use Committee of the Free University of Brussels. Male NMRI mice (Charles River, Les Oncins, France), 6 to 10 weeks old (35Y40 g), were used for all the experiments. Animals were housed at least 1 week before the experiment and were maintained under standard laboratory conditions. After surgery, the mice were housed 1 per cage in a temperature-controlled room with food and water provided ad libitum and were kept on a 12-h light/12-h dark diurnal cycle.
Cecal ligation and puncture
Mice were anesthetized with intraperitoneal ketamine (100 2g/g) (Ketalar) and xylazine (13 2g/g) (Rompun). Under sterile conditions, a 2-cm midline incision was made through the linea alba. The cecum was located, ligated with 3-0 silk, and perforated twice with a 19-gauge needle. A small amount of stool was extruded to ensure wound patency. The cecum was then replaced in its original position within the abdomen, which was closed in 2 layers. Surgery lasted around 20 min, during which the mice were kept on a heating pad. Once animals started to recover from the anesthesia, warm saline (50 mL/kg) with buprenorphine (0.01 mg/kg) was administered subcutaneously. In preliminary experiments, we determined that the mortality in this model without treatment is 60% at 48 h and 80% by day 5.
Experiment
Mice were randomly allocated to treatment with saline or dexamethasone (Aacidexam, Organon, Brussels, Belgium) at a dose of 0.1, 1, or 10 mg/kg. Treatments were injected intraperitoneally immediately after surgery.
Mice were euthanized at 6 or 18 h after surgery under deep-inhalation anesthesia with isoflurane, followed by cardiac puncture. Ten other mice were euthanized at time 0 without undergoing any procedure, and their samples were used as baseline. A peritoneal lavage was performed with 3 mL ice-cold saline.
Finally, samples from liver, lungs, kidneys, and heart were collected by autopsy and frozen in liquid nitrogen. Heparinized blood and peritoneal lavage fluid (PLF) were centrifuged, and the plasma and cell-free peritoneal lavage fluid were frozen at j20-C until use.
Tissues were homogenized with a RW 20.n stirrer (IKA Werke, Staufen, Germany) in ice-cold CelLytic-MT Mammalian Tissue Lysis/Extraction Reagent (0.75 mL) with protease inhibitor mixture (Sigma Chemical Co, St. Louis, Mo) and then centrifuged at 10,000g for 10 min.
In additional experiments, we studied the effect of treatment with dexamethasone 10 mg/kg on MIF intracellular expression in peripheral blood mononuclear cells (PBMCs) withdrawn from mice after 18 h (the setting in which we found decreased MIF plasma levels in response to dexamethasone 10 mg/kg). Three groups of mice were studied in this way (5 in each group): cecal ligation and puncture (CLP) plus saline, CLP plus dexamethasone, and healthy mice plus dexamethasone. PBMCs were isolated from heparinized blood after centrifugation in Lymphoprep (Accurate Chemical and Scientific Corporation, Westbury, NY) at 800g for 20 min. PBMCs were resuspended in Hanks balanced salt solution without Ca 2+ or Mg 2+ , counted, and centrifuged at 250g for 10 min. Thereafter, they were resuspended in phosphate-buffered saline (PBS) at 8 Â 10 6 cells/mL and lysed using 3 freeze/thaw cycles. Thereafter, the lysed solution was centrifuged at 13,000 rpm and the supernatants separated for analysis.
MIF and cytokine quantification by ELISA
MIF levels in plasma, PLF, and tissue homogenates were measured by an MIFspecific sandwich enzyme-linked immunosorbent assay (ELISA) method with purified mouse rMIF (gift from Dr Thierry Calandra) as standard. Briefly, 96-well ELISA plates (Maxisorb Nunc, Roskilde, Denmark) were coated with 5 2g/mL of polyclonal rabbit antirat MIF antibody (AP 234, Torrey Pines, San Marcos, Calif) in PBS overnight at room temperature. The plates were then washed and blocked with a solution containing bovine serum albumin 1%, sucrose 5%, and sodium azide 0.05%. After an additional wash in PBSY0.05% Tween-20, the diluted samples and the standards were plated in duplicate and incubated for 2 h at room temperature. The plates were then washed, and detector goat antihuman MIF biotinylated Affinity Purified (BAF289, R&D Systems Europe, Abingdon, UK), which cross-reacts with mouse MIF, was added at 1.5 2g/mL for 2 h at room temperature. After a wash in PBSY0.05% Tween-20, streptavidin peroxidase conjugate was added at a 1:100 dilution for 30 min at room temperature. Captured streptavidin-antibody complexes were detected by the addition of stabilized tethramethylbenzidine Yhydrogen peroxide substrate, and the positive signals were read at 450 nm against a standard curve obtained for rMIF. Data for tissues are normalized as values in nanogram of MIF per milligram of total protein, measured by using the Bio-Rad Protein Assay Kit II (Bio-Rad, Hercules, Calif) with a bovine serum albumin standard curve. Quantifications of IL-6, IL-10, and TNF-! were performed with commercially available ELISA kits according to the manufacturer's instructions (Duoset, R&D Systems Europe, for IL-6 and TNF-!; BioSource International Europe, Nivelles, Belgium, for IL-10).
MIF Western blot
For Western blotting, 5 2L of pooled plasma from each group (8 Y10 mice per group) were resolved on 15% sodium dodecyl sulfate polyacrylamide gels under reducing conditions and transferred onto Hybond-P PVDF (RPN 2020F, Amersham Biosciences, Piscataway, NJ) at 24 V and 320 mA for 30 min using a semidry transfer apparatus. Membranes were blocked for 1 h with PBS buffer containing 5% nonfat dry milk and 0.05% Tween-20 and incubated, first with polyclonal rabbit antirat MIF antibody (AP 234) diluted 1:1000 in block buffer overnight at 4-C and then with horseradish peroxidaseYconjugated goat antirabbit IgG antibody diluted 1:10,000 in blocking buffer, for 1 h at room temperature. MIF was visualized by development with SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, Ill). Ten nanograms of rMIF standard was run on the same sodium dodecyl sulfate gels.
Statistical analysis
Data are presented as mean T SEM. One-way ANOVA with Dunnett post-test was performed using GraphPad Prism version 3.03 for Windows (GraphPad Software, San Diego, Calif).
RESULTS
Plasma
CLP induced an increase in plasma MIF levels from 6.0 T 1.8 ng/mL at baseline to 58.5 T 18.5 and 69.1 T 16.8 ng/mL at 6 and 18 h, respectively (P = 0.01), in the saline-treated group (baseline data not represented on Fig. 1) . TNF-!, IL-6, and IL-10 were undetectable at baseline but were detected at high concentrations at 6 and 18 h post-CLP.
Dexamethasone administration did not influence MIF plasma levels at 6 h, but decreased them at 18 h in the group with 10 mg/kg dose. The analysis of pooled plasma samples from each group by Western blot gave similar results to the ELISA-derived data (data not shown). High doses of Treatments were compared by 1-way ANOVA (corresponding P values shown over rthe bars) followed by a Dunnett post-test when appropriate. Data are mean T SEM; n = 9 to 10 mice per group at each time point. *P G 0.05 compared to saline group. dexamethasone administration decreased TNF-! and IL-6 levels at 6 h, but did not influence IL-10 levels (Fig. 1) .
Peritoneal lavage fluid
CLP induced an increase in PLF MIF levels from 1.4 T 0.2 ng/mL at baseline to 21.6 T 4.8 and 19.4 T 3.2 ng/mL at 6 and 18 h, respectively (P G 0.01), in the saline treated group (baseline data not represented on Fig. 2) . TNF-!, IL-6, and IL-10 were undetectable at baseline but rose markedly at 6 and 18 h post-CLP.
Dexamethasone had no effect on PLF MIF levels. IL-6 and TNF-! levels tended to decrease, although this effect was statistically significant only for TNF-! at 6 h in the 10-mg/kg group. Low doses of dexamethasone resulted in a substantial increase in IL-10 at 6 h.
Tissues and PBMC
CLP induced a marked increase in MIF protein expression in the kidney but no significant change in the liver, lung, and heart (Table 1) . Dexamethasone had no effect on MIF protein expression in any of these tissues (Fig. 3) . In PBMCs, dexamethasone treatment (in the 10-mg/kg group) was associated with a trend to decreased intracellular expression of MIF compared to saline treatment at 18 h (Fig. 4) .
DISCUSSION
We studied the effects of glucocorticoid administration in a mouse peritonitis sepsis model. This model is associated with a marked increase in MIF concentrations in the plasma and the PLF. Glucocorticoids are thought to contribute to the rise in MIF levels in sepsis (4). We found that dexamethasone treatment had no effect on MIF production either locally in the peritoneal cavity or in the liver, lungs, or heart; furthermore, dexamethasone 10 mg/kg decreased MIF plasma levels after 18 h.
These data seem to contradict the current understanding of how glucocorticoids regulate MIF production. In various in vitro and in vivo studies, Calandra et al and other groups of investigators showed that glucocorticoids induce the synthesis and the release of MIF (4, 5, 11, 12) , but these observations were made in physiological conditions, in the absence of inflammation.
We showed a different response in sepsis. Our findings had already been suggested by 3 recent studies on the effects of glucocorticoids on MIF production in acute inflammation. In a rat model of balloon aortic injury, Nagasaki et al reported that methylprednisolone did not increase but rather tended to decrease serum MIF levels (13) . Mendonca-Filho et al reported that the administration of 15 mg/kg methylprednisolone seemed to decrease blood MIF concentrations in patients undergoing cardiopulmonary bypass (14) . Maxime et al recently studied ex vivo PBMC from septic shock patients included in a randomized controlled trial of low-dose 
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Data are mean T SEM; n = 9 to 10 mice per group at each time point. Data at 6 and 18 h correspond to the saline-treated group. Time points were compared by 1-way ANOVA, and the P value is reported in the right column. *P G 0.05 and † P G 0.01 compared to baseline after Dunnett post-test. T6 indicates 6 h after CLP; T18, 18 h after CLP.
hydrocortisone versus placebo (15) . These authors found that glucocorticoid treatment downregulated the level of cellassociated MIF and MIF release by various activators, including endotoxin (15) .
Although MIF is normally present in blood and several tissues and cell types, its production and release are markedly increased during inflammation induced by LPS or proinflammatory cytokines (16Y18). Endogenous glucocorticoids can also be implicated. Sepsis and other inflammatory states activate the hypothalamic-pituitary-adrenal axis, resulting in increased blood levels of glucocorticoids (2) . It is possible that, in these conditions, the mechanism of direct stimulation of glucocorticoids on MIF is already maximal, so that exogenous glucocorticoids cannot further increase MIF production. This is consistent with data from in vitro experiments where glucocorticoid upregulation of MIF followed a bell-shaped dose-response curve, with a maximal effect at dexamethasone concentrations of 10 j12 mol/L but no response over 10 j8 mol/L (4). Alternatively, the glucocorticoid effect on MIF release may not be a general feature, even without inflammation. Calandra et al first described this regulation in cultured rat RAW 264.7 macrophages and in murine monocytes and T lymphocytes (4). However, Alourfi et al in 2 human cell lines in vitro found no evidence for such a regulation but actually found the opposite effect (19) . Furthermore, they were not able to confirm the original description by Calandra et al in RAW 264.7 cells (19) . In addition, Maxime et al failed to observe that dexamethasone induces MIF release from PBMCs of healthy humans (15) . Likewise, although increased circulating MIF levels in response to the administration of dexamethasone or activation of the hypothalamic-pituitary-adrenal axis have been shown in rats, such regulation has not been confirmed in humans (20) . Thus, glucocorticoid regulation of MIF synthesis and release seems to be cell typeYspecific, species-specific, and highly complex.
We looked at MIF protein expression in the liver, lung, heart, and kidneys because the function of these organs is often compromised in sepsis and particularly in the CLP model (21) . We found a moderate increase in MIF expression in the kidney but no significant change in the other organs. Dexamethasone had no effect on MIF protein expression in any of the organs studied.
The finding of decreased MIF plasma levels at 18 h in the group with 10 mg/kg dexamethasone treatment was not associated with similar changes in MIF levels in the peritoneal cavity or tissues and, therefore, cannot be explained by a lower release from these sites. Recently, circulating blood cells such as monocytes, lymphocytes, and neutrophils have been implicated as a source of increased serum MIF levels during sepsis (15, 22) . Moreover, as referred to earlier, Maxime et al showed that glucocorticoid treatment decreases the production of MIF by PBMC from septic shock patients (15) . Therefore, we decided to repeat the experiment at 18 h and investigate whether dexamethasone treatment decreased intracellular MIF expression in the PBMC of the septic mice (we only studied the effect of 10 mg/kg dexamethasone because this was the dose that significantly decreased MIF plasma levels at 18 h). We found that dexamethasone decreased MIF expression in PBMC only slightly, and the changes were not statistically significant.
It was described previously that nonspecific soluble factors present in mouse plasma may interfere with MIF ELISA assays (6) . Therefore, we decided to confirm our results on MIF plasma levels by Western blot. The analysis of pooled plasma samples from each group gave similar results to the ELISA-derived data.
Our data, together with data from others, show that the ability of glucocorticoids to stimulate MIF production, as previously described in healthy animals (4, 5) , is not present during inflammatory states. These discordant data may fit into the dual role proposed for MIF as a hormone and cytokine (23) . Under physiological conditions, MIF may act predominantly as a hormone, and its production is induced by glucocorticoids. In contrast, during inflammation, MIF production is increased and it acts as a proinflammatory cytokine. Under these circumstances, glucocorticoids no longer upregulate MIF production. We conclude that dexamethasone does not increase MIF production in sepsis.
